Diana Bilton is Honorary Clinical Senior Lecturer and Director of the Adult Cystic Fibrosis Service at Royal Brompton Hospital.
Diana trained in Manchester graduating in 1984.After completing general training she became a UK Cystic Fibrosis Trust research fellow with Professor Kevin Webb examining the influence of antioxidant status on pulmonary and pancreatic disease . This early research inspired Diana's career long interest in evaluating new diagnostic and therapeutic approaches to the continued vicious cycle of infection and inflammation in Cystic Fibrosis and Non CF Bronchiectasis.
Diana has been global chief investigator on trials of new therapies for Cystic Fibrosis and nonCF Bronchiectasis. Recent studies have included randomised trials of Inhaled Dry Powder Mannitol as well as investigation of novel inhaled antibiotic preparations.
Diana is joint PI with Dr Jane Davies of the European CF Society Clinical Trials Network site at Royal Brompton .
et al., 2021, Heterogeneity of treatment response in bronchiectasis clinical trials., Eur Respir J
et al., 2021, Incidence and risk factors of cancer in individuals with cystic fibrosis in the UK; a case-control study., Journal of Cystic Fibrosis, ISSN:1569-1993
et al., 2021, Long-term amikacin liposome inhalation suspension in cystic fibrosis patients with chronic P. aeruginosa infection., J Cyst Fibros
et al., 2021, The fungal airway microbiome in cystic fibrosis and non-cystic fibrosis bronchiectasis, Journal of Cystic Fibrosis, Vol:20, ISSN:1569-1993, Pages:295-302
et al., 2021, Long-term safety study of colistimethate sodium (Colobreathe?): Findings from the UK Cystic Fibrosis Registry, Journal of Cystic Fibrosis, Vol:20, ISSN:1569-1993, Pages:324-329